Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 August, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 532989 | NSE: BAFNAPH

Bafna Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 9:17 pm

Market Cap 246 Cr.
Current Price 104
High / Low 117/67.8
Stock P/E24.4
Book Value 35.8
Dividend Yield0.00 %
ROCE8.28 %
ROE7.61 %
Face Value 10.0
PEG Ratio2.55

Quick Insight

Bafna Pharmaceuticals Ltd, with a current share price of 99.5 and a market capitalization of 232 Cr., presents a mixed financial picture. The company's P/E ratio stands at 23.0, indicating a moderate valuation, while the ROE and ROCE figures at 7.61% and 8.28% respectively suggest room for improvement in profitability. Furthermore, the negative P/BV of -0.49x raises concerns about the stock's book value. With a high promoter holding of 88.29% and low institutional ownership, the stock may lack broader market confidence. Despite a healthy ICR of 15.48x, the company's borrowing of ₹28Cr is noteworthy given its size. In conclusion, while Bafna Pharmaceuticals Ltd shows potential, investors should carefully consider its financial metrics before making investment decisions.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Bafna Pharmaceuticals Ltd

Competitors of Bafna Pharmaceuticals Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Lactose (India) Ltd 141 Cr. 112 247/84.332.1 46.70.00 %12.9 %9.75 % 10.0
MPS Pharmaa Ltd 4.09 Cr. 2.14 4.33/2.14 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 4,163 Cr. 382 411/19293.4 22.80.18 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 31.3 Cr. 42.2 94.9/39.0 8.730.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 30.8 Cr. 21.0 29.1/17.032.1 6.830.00 %13.5 %11.0 % 10.0
Industry Average18,550.89 Cr1,158.7047.60193.710.33%16.34%15.08%6.18

All Competitor Stocks of Bafna Pharmaceuticals Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 16.9321.9634.2242.2441.9540.6828.4441.4033.2940.3233.1939.0634.62
Expenses 15.2719.4231.1834.6235.6636.6730.5138.5132.0836.5330.1335.9529.55
Operating Profit 1.662.543.047.626.294.01-2.072.891.213.793.063.115.07
OPM % 9.81%11.57%8.88%18.04%14.99%9.86%-7.28%6.98%3.63%9.40%9.22%7.96%14.64%
Other Income 1.300.641.930.261.870.160.980.520.161.020.18-0.760.60
Interest 0.310.450.580.700.600.440.580.680.650.620.640.820.91
Depreciation 1.291.121.401.531.211.241.271.271.441.581.660.221.37
Profit before tax 1.361.612.995.656.352.49-2.941.46-0.722.610.941.313.39
Tax % -0.00%-0.00%-0.00%4.96%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%
Net Profit 1.361.613.005.376.352.48-2.941.46-0.722.620.951.313.39
EPS in Rs 0.570.681.272.272.681.05-1.240.62-0.301.110.400.551.43

Last Updated: August 20, 2025, 1:15 pm

Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

  • For Sales, as of Jun 2025, the value is 34.62 Cr.. The value appears to be declining and may need further review. It has decreased from 39.06 Cr. (Mar 2025) to 34.62 Cr., marking a decrease of 4.44 Cr..
  • For Expenses, as of Jun 2025, the value is 29.55 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.95 Cr. (Mar 2025) to 29.55 Cr., marking a decrease of 6.40 Cr..
  • For Operating Profit, as of Jun 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 3.11 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 1.96 Cr..
  • For OPM %, as of Jun 2025, the value is 14.64%. The value appears strong and on an upward trend. It has increased from 7.96% (Mar 2025) to 14.64%, marking an increase of 6.68%.
  • For Other Income, as of Jun 2025, the value is 0.60 Cr.. The value appears strong and on an upward trend. It has increased from -0.76 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 1.36 Cr..
  • For Interest, as of Jun 2025, the value is 0.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Mar 2025) to 0.91 Cr., marking an increase of 0.09 Cr..
  • For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.22 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 1.15 Cr..
  • For Profit before tax, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
  • For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
  • For Net Profit, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
  • For EPS in Rs, as of Jun 2025, the value is 1.43. The value appears strong and on an upward trend. It has increased from 0.55 (Mar 2025) to 1.43, marking an increase of 0.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:26 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 17710085654644427185115152146147
Expenses 15611682708157416173100141135132
Operating Profit 21-163-5-35-131101216111115
OPM % 12%-16%3%-8%-77%-30%3%14%14%14%7%8%10%
Other Income 14011310-231-03411
Interest 12121211720112233
Depreciation 8544433455555
Profit before tax 26-13-19-14-18-256512748
Tax % 40%-0%-3%-4%15%8%0%0%0%2%0%0%
Net Profit 16-12-18-16-20-256511748
EPS in Rs 0.723.28-6.53-9.90-6.95-8.34-106.532.462.214.793.111.753.49
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)500.00%-300.00%-50.00%11.11%-25.00%-25.00%124.00%-16.67%120.00%-36.36%-42.86%
Change in YoY Net Profit Growth (%)0.00%-800.00%250.00%61.11%-36.11%0.00%149.00%-140.67%136.67%-156.36%-6.49%

Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:28%
3 Years:20%
TTM:2%
Compounded Profit Growth
10 Years:8%
5 Years:40%
3 Years:-5%
TTM:1498%
Stock Price CAGR
10 Years:14%
5 Years:35%
3 Years:-3%
1 Year:29%
Return on Equity
10 Years:-10%
5 Years:11%
3 Years:11%
Last Year:8%

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 1:41 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 19191919242422424242424
Reserves 5053412617-3493338505761
Borrowings 99648082474631511232428
Other Liabilities 545045404054171417334240
Total Liabilities 223185185167128121718690130148153
Fixed Assets 634947434037353639404059
CWIP -0-0-0-0-0-001-02127
Investments 118181811-0-0-0-0-0-0
Other Assets 1581181201068682365051889587
Total Assets 223185185167128121718690130148153

Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
  • For Reserves, as of Mar 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 4.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 28.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 28.00 Cr., marking an increase of 4.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 40.00 Cr.. The value appears to be improving (decreasing). It has decreased from 42.00 Cr. (Mar 2024) to 40.00 Cr., marking a decrease of 2.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 153.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Mar 2024) to 153.00 Cr., marking an increase of 5.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 59.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 59.00 Cr., marking an increase of 19.00 Cr..
  • For CWIP, as of Mar 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2024) to 7.00 Cr., marking a decrease of 5.00 Cr..
  • For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 95.00 Cr. (Mar 2024) to 87.00 Cr., marking a decrease of 8.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 153.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2024) to 153.00 Cr., marking an increase of 5.00 Cr..

Notably, the Reserves (61.00 Cr.) exceed the Borrowings (28.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +19-314-7-1-34-14105922
Cash from Investing Activity +-556-1-838433-5-7-7-15-21
Cash from Financing Activity +-14-664-5-31-2712-510-11
Net Cash Flow-18-00-0006-7-28-62

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-78.00-80.00-77.00-87.00-82.00-59.00-2.00-5.001.00-7.00-13.00-17.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days192303291302195208524963130109101
Inventory Days786692118102122208154185129125127
Days Payable116149169164265517229107113165149140
Cash Conversion Cycle15522021425531-1883196135948488
Working Capital Days4156125-36-108-210891211231049374
ROCE %9%-13%-0%-6%-35%-21%-3%10%11%16%9%8%

Financial Efficiency Indicators Chart

No valid data available for the Shareholding

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 20Mar 19Mar 18Mar 17Mar 16
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -15.52-11.48-7.15-10.43-8.80
Diluted EPS (Rs.) -15.52-11.48-7.15-10.43-8.80
Cash EPS (Rs.) -89.52-6.29-5.47-8.17-5.51
Book Value[Excl.RevalReserv]/Share (Rs.) -17.597.9715.7322.5730.95
Book Value[Incl.RevalReserv]/Share (Rs.) -17.597.9715.7322.5730.95
Revenue From Operations / Share (Rs.) 179.5418.3319.9434.8245.73
PBDIT / Share (Rs.) 6.25-5.36-1.61-2.501.34
PBIT / Share (Rs.) -7.56-6.83-3.29-4.76-1.27
PBT / Share (Rs.) -103.32-7.30-6.22-10.91-8.21
Net Profit / Share (Rs.) -103.32-7.76-7.15-10.43-8.12
NP After MI And SOA / Share (Rs.) -104.54-7.98-7.07-10.23-7.52
PBDIT Margin (%) 3.48-29.26-8.05-7.182.92
PBIT Margin (%) -4.20-37.28-16.47-13.68-2.76
PBT Margin (%) -57.54-39.86-31.19-31.34-17.95
Net Profit Margin (%) -57.54-42.32-35.84-29.95-17.74
NP After MI And SOA Margin (%) -58.22-43.52-35.48-29.38-16.44
Return on Networth / Equity (%) 0.00-99.01-44.12-44.73-24.28
Return on Capital Employeed (%) -3.29-33.22-9.90-9.17-2.41
Return On Assets (%) -34.67-15.79-12.09-10.70-7.27
Long Term Debt / Equity (X) -0.711.210.610.910.60
Total Debt / Equity (X) -0.712.431.231.931.39
Asset Turnover Ratio (%) 0.440.330.300.360.44
Current Ratio (X) 2.110.680.810.941.29
Quick Ratio (X) 1.440.550.630.741.11
Inventory Turnover Ratio (X) 2.242.661.550.890.97
Interest Coverage Ratio (X) 15.48-5.97-0.54-0.400.19
Interest Coverage Ratio (Post Tax) (X) -18.72-8.10-1.44-0.69-0.16
Enterprise Value (Cr.) -3.2969.21109.10134.30133.55
EV / Net Operating Revenue (X) -0.071.602.312.071.57
EV / EBITDA (X) -2.22-5.45-28.71-28.7653.52
MarketCap / Net Operating Revenue (X) 0.040.591.400.840.65
Price / BV (X) -0.491.361.751.290.96
Price / Net Operating Revenue (X) 0.040.591.400.840.65
EarningsYield -11.80-0.72-0.25-0.34-0.25

After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
  • For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
  • For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
  • For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
  • For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
  • For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
  • For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
  • For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
  • For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
  • For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
  • For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
  • For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
  • For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
  • For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
  • For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
  • For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
  • For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
  • For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
  • For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
  • For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
  • For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
  • For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
  • For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
  • For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
  • For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
  • For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
  • For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
  • For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
  • For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
  • For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
  • For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bafna Pharmaceuticals Ltd as of August 30, 2025 is: 54.24

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 30, 2025, Bafna Pharmaceuticals Ltd is Overvalued by 47.85% compared to the current share price 104.00

Intrinsic Value of Bafna Pharmaceuticals Ltd as of August 30, 2025 is: 59.43

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 30, 2025, Bafna Pharmaceuticals Ltd is Overvalued by 42.86% compared to the current share price 104.00

Last 5 Year EPS CAGR: 9.57%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
    1. The stock has a low average ROCE of -1.25%, which may not be favorable.
    2. The stock has a high average Working Capital Days of 39.33, which may not be favorable.
    3. The stock has a high average Cash Conversion Cycle of 101.25, which may not be favorable.
    4. The company has higher borrowings (43.50) compared to reserves (39.33), which may suggest financial risk.
    5. The company has not shown consistent growth in sales (98.08) and profit (-3.00).

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
      1. Net Profit Margin: -57.54%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: -3.29% (Industry Average ROCE: 16.34%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 0% (Industry Average ROE: 15.08%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): -18.72
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 1.44
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 24.4 (Industry average Stock P/E: 47.6)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: -0.71
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 145.86 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2025.
    INDUSTRYADDRESSCONTACT
    PharmaceuticalsBafna Towers, New�No.�68,�Old�No. 299,�� � Chennai (Madras) Tamil Nadu 600001info@bafnapharma.com
    http://www.bafnapharma.com
    Management
    NamePosition Held
    Mrs. S HemalathaWhole Time Director
    Mrs. Akila C RajuNon Exe.Non Ind.Director
    Ms. R ChitraInd. Non-Executive Director
    Mr. B Kamlesh KumarInd. Non-Executive Director
    Mr. P K SundaresanInd. Non-Executive Director
    Mr. Vinayak Dinesh DendukuriWhole Time Director
    Mr. Upendar Mekala ReddyNon Exe.Non Ind.Director
    Mr. Krishna YeachuriInd. Non-Executive Director

    FAQ

    What is the intrinsic value of Bafna Pharmaceuticals Ltd?

    Bafna Pharmaceuticals Ltd's intrinsic value (as of 30 August 2025) is 54.24 which is 47.85% lower the current market price of ₹104.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹246 Cr. market cap, FY2025-2026 high/low of 117/67.8, reserves of ₹61 Cr, and liabilities of 153 Cr.

    What is the Market Cap of Bafna Pharmaceuticals Ltd?

    The Market Cap of Bafna Pharmaceuticals Ltd is 246 Cr..

    What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 30 August 2025?

    The current stock price of Bafna Pharmaceuticals Ltd as on 30 August 2025 is 104.

    What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2025-2026?

    In FY 2025-2026, the High / Low of Bafna Pharmaceuticals Ltd stocks is 117/67.8.

    What is the Stock P/E of Bafna Pharmaceuticals Ltd?

    The Stock P/E of Bafna Pharmaceuticals Ltd is 24.4.

    What is the Book Value of Bafna Pharmaceuticals Ltd?

    The Book Value of Bafna Pharmaceuticals Ltd is 35.8.

    What is the Dividend Yield of Bafna Pharmaceuticals Ltd?

    The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.

    What is the ROCE of Bafna Pharmaceuticals Ltd?

    The ROCE of Bafna Pharmaceuticals Ltd is 8.28 %.

    What is the ROE of Bafna Pharmaceuticals Ltd?

    The ROE of Bafna Pharmaceuticals Ltd is 7.61 %.

    What is the Face Value of Bafna Pharmaceuticals Ltd?

    The Face Value of Bafna Pharmaceuticals Ltd is 10.0.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bafna Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE